title: Type 2B von Willebrand's disease due to Val1316Met mutation. Heterogeneity in the same sibship.
abstract: An analysis was conducted in four members of the same family, two of whom had a history of severe bleeding associated with type 2B von Willebrand's disease (VWD) which, although found to be due to the same mutation, nevertheless exhibited different phenotype patterns in the two subjects involved. Von Willebrand's factor (VWF) multimers were assayed with high- and low-resolution sodium dodecyl sulfate (SDS) agarose gels. The patients were studied before and after intravenous administration of desmopressin (DDAVP) at doses of 0.4 microg/kg body weight. Automatic sequencing techniques were used to analyze VWF gene exon 28. The propositus presented with mild basal thrombocytopenia with ristocetin-induced platelet aggregation (RIPA) at low concentrations of ristocetin. He had a very prolonged bleeding time (BT), and his plasma VWF was found to be lacking in large and intermediate multimers. Thrombocytopenia was observed to intensify transiently after the administration of DDAVP. The propositus' mother, in contrast, presented reduced RIPA while in a basal state, with only partial loss of the high molecular weight VWF multimers. Although she had a very prolonged BT, her platelet count was borderline. Transient correction of BT and a decrease in the platelet count were observed after administration of DDAVP and RIPA was observed at low concentrations of ristocetin. Exon 28 sequencing revealed a G4196A-->Val1316Met mutation in both patients. No other abnormality was detected within this exon. Val1316Met has been reported in type 2B VWD. In conclusion, in the family presented here, the phenotype pattern in one patient was typical of type 2B VWD, whereas the pattern in his mother was closer to type 2A VWD. After administration of DDAVP, however, a type 2B phenotype could be clearly attributed to both, indicating that this drug can be a useful tool for elucidating ambiguous phenotypes.
authors.affiliation: Servicio de Hematología, Hospital Teresa Herrera, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Rendal
authors.forename: N
authors.initials: N
authors.lastname: Penas
authors.forename: B
authors.initials: B
authors.lastname: Larrabeiti
authors.forename: A
authors.initials: A
authors.lastname: Pérez
authors.forename: A
authors.initials: A
authors.lastname: Vale
authors.forename: M F
authors.initials: MF
authors.lastname: López-Fernández
authors.forename: J
authors.initials: J
authors.lastname: Batlle
mesh_terms: D000328:Adult; D019943:Amino Acid Substitution; D016022:Case-Control Studies; D004252:DNA Mutational Analysis; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage / Q000494:pharmacology; D005192:Family Health; D018740:Genetic Heterogeneity; D006801:Humans; D008297:Male; D009154:Mutation; D010375:Pedigree; D010641:Phenotype; D010979:Platelet Function Tests; D013921:Thrombocytopenia / Q000139:chemically induced / Q000209:etiology; D014842:von Willebrand Diseases / Q000145:classification / Q000188:drug therapy / Q000235:genetics*
chemical_list: D003894:Deamino Arginine Vasopressin